You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection
SBC: MKS Technology Topic: NIDADESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Reduced gluten cereal grains
SBC: Arcadia Biosciences, Inc. Topic: 300DESCRIPTION provided by applicant Celiac disease CD is the most common food sensitive enteropathy known affecting approximately of the population and its incidence appears to be on the rise In addition non celiac gluten sensitivity GS has recently been revealed to be a distinct condition that affects a growing number of individuals Both of these conditions are triggered by gluten a ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Synactix Pharmaceuticals I-Corps Application
SBC: SYNACTIX PHARMACEUTICALS, INC. Topic: 102DESCRIPTION provided by applicant Polypharmacology represents a new and attractive approach to treat malignances as lasting and robust efficacy could be obtained through the inhibition of multiple survival pathways with one therapeutic agent In line with this method we have designed a RET rearranged during transfection VEGFR vascular endothelial growth factor receptor small molecule ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.
SBC: PROMUTECH PHARMACEUTICALS, INC. Topic: 102DESCRIPTION provided by applicant Pathological activating mutations in the FLT kinase represent the most common genetic alteration in patients with acute myeloid leukemia AML occurring in approximately one third of cases Recently we performed translational studies that identified drug resistant kinase domain mutations in FLT ITD at the time of relapse in AML patients treated with the FLT ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Extraction and Characterization of a Safer, Cost-effective Anti-inflammatory
SBC: Botanisol LLC Topic: RDESCRIPTION provided by applicant Inflammatory disease states are leading causes of death and disability and a major cost to healthcare in the United States There is an epidemic of death and hospitalizations due to adverse effects from NSAIDs TAI LCx Turmeric Anti Inflammatory Lipophilic Component X is a novel anti inflammatory discovered in previously unrecognized pharmacologically activ ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
AFARI: A Stylized Adaptive Mobility and Fitness Device for Outdoor Movement
SBC: R M BEAUMONT CORP Topic: NIADESCRIPTION provided by applicant Osteoarthritis OA diagnosed in over of the US population is the primary cause of musculoskeletal lower extremity disability Although there is no cure exercise remains the core treatment to manage OA regardless of age comorbidity pain severity or disability Yet many people with this condition do not engage in regular fitness and thus may resort t ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
NET- Selective Ligands for the Treatment of Depression
SBC: Acenta Discovery, Inc. Topic: N/ADESCRIPTION (provided by applicant): World-wide public health surveys point to an increased global health burden for serious psychiatric disorders, particularly depression. Indeed, by 2020 it is expected that depression may be the second most serious medical condition with respect to global disease burden. It is clear that more effective pharmacotherapies are needed in treating depressive illn ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Detection of Multiple Chemical Warfare Agents
SBC: CC Technology Topic: N/ADESCRIPTION (provided by applicant): The goal of this Phase I STTR project is the development of an analytical method for the rapid detection of a variety of chemical warfare (CW) agents. A large number of methods have been used for the detection of CW agents, but they are generally not well suited for use under battlefield conditions, due to size, speed of analysis, power requirements or fragilit ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Carbonyl scavengers for skin protection from glycation
SBC: NIADYNE, INC. Topic: N/ADESCRIPTION (provided by applicant): This phase I STTR application provides the technical basis for the commercial development of glycation inhibitors as novel protective agents against pathological skin conditions characterized by increased glycation damage. Glycation, the spontaneous reaction of cellular constituents with reducing sugars and other reactive carbonyl species (RCS), has been ident ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health